Emodin enhances sensitivity of gallbladder cancer cells to platinum drugs via glutathion depletion and MRP1 downregulation

Biochemical Pharmacology

Volumn 79, Issue 8, 2010, Pages 1134-1140

  Wang, Wei ^a   Sun, Yue ping ^b   Huang, Xin zhi ^b   He, Min ^a   Chen, Yu ying ^b   Shi, Gui ying ^b   Li, Hui ^b   Yi, Jing ^b   Wang, Jian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cisplatin; Emodin; Gallbladder cancer; Glutathione; MRP1

Indexed keywords

CARBOPLATIN; CISPLATIN; EMODIN; GLUTATHIONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; CONJUGATION; CONTROLLED STUDY; DOWN REGULATION; DRUG DETOXIFICATION; DRUG POTENTIATION; DRUG SENSITIVITY; GALLBLADDER CANCER; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; EMODIN; GALLBLADDER NEOPLASMS; GLUTATHIONE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPLATINUM COMPOUNDS; REACTIVE OXYGEN SPECIES;

EID: 77249157217     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.12.006     Document Type: Article

References (34)

1. Patel T. Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 2006, 3:33-42.
2. Reddy S.B., Patel T. Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 2006, 8:30-37.
3. Daines W.P., Rajagopalan V., Grossbard M.L., Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, Part 2. Oncology (Williston Park) 2004, 18:1049-1059. [discussion 60, 65, 66, 68].
4. Gold D.G., Miller R.C., Haddock M.G., Gunderson L.L., Quevedo F., Donohue J.H., et al. Adjuvant therapy for gallbladder carcinoma: the Mayo clinic experience. Int J Radiat Oncol Biol Phys 2009, 75:150-155.
5. Andre T., Reyes-Vidal J.M., Fartoux L., Ross P., Leslie M., Rosmorduc O., et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008, 99:862-867.
6. Makiyama A., Qin B., Uchino K., Shibata Y., Arita S., Isobe T., et al. Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines. Anticancer Drugs 2009, 20:123-130.
7. Kim M.J., Oh D.Y., Lee S.H., Kim D.W., Im S.A., Kim T.Y., et al. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 2008, 8:374.
8. Torigoe T., Izumi H., Ishiguchi H., Yoshida Y., Tanabe M., Yoshida T., et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005, 5:15-27.
9. Hall M.D., Okabe M., Shen D.W., Liang X.J., Gottesman M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008, 48:495-535.
10. Cai J., Niu X., Chen Y., Hu Q., Shi G., Wu H., et al. Emodin-induced generation of reactive oxygen species inhibits RhoA activation to sensitize gastric carcinoma cells to anoikis. Neoplasia 2008, 10:41-51.
11. Yang J., Li H., Chen Y.Y., Wang X.J., Shi G.Y., Hu Q.S., et al. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic Biol Med 2004, 37:2027-2041.
12. Yi J., Yang J., He R., Gao F., Sang H., Tang X., et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004, 64:108-116.
13. Huang X.Z., Wang J., Huang C., Chen Y.Y., Shi G.Y., Hu Q.S., et al. Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biol Ther 2008, 7:468-475.
14. Zhang K., Mack P., Wong K.P. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998, 12:871-882.
15. Ishikawa T., Bao J.J., Yamane Y., Akimaru K., Frindrich K., Wright C.D., et al. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996, 271:14981-14988.
16. Byun S.S., Kim S.W., Choi H., Lee C., Lee E. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int 2005, 95:1086-1090.
17. Jing Y., Yang J., Wang Y., Li H., Chen Y., Hu Q., et al. Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. Free Radic Biol Med 2006, 40:2183-2197.
18. Stavrovskaya A.A., Stromskaya T.P. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 2008, 73:592-604.
19. Chen C.J., Chin J.E., Ueda K., Clark D.P., Pastan I., Gottesman M.M., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986, 47:381-389.
20. Munoz M., Henderson M., Haber M., Norris M. Role of the MRP1/ABCC1 multidrug transporter protein in cancer. IUBMB Life 2007, 59:752-757.
21. Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92:1295-1302.
22. Abaan O.D., Mutlu P.K., Baran Y., Atalay C., Gunduz U. Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients. Cancer Invest 2009, 27:201-205.
23. Ishikawa T., Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 1993, 268:20116-20125.
24. Hait W.N., Yang J.M. The individualization of cancer therapy: the unexpected role of p53. Trans Am Clin Climatol Assoc 2006, 117:85-101. [discussion].
25. Iida T., Kijima H., Urata Y., Goto S., Ihara Y., Oka M., et al. Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther 2001, 8:803-814.
26. Konstantakou E.G., Voutsinas G.E., Karkoulis P.K., Aravantinos G., Margaritis L.H., Stravopodis D.J. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol 2009, 35:401-416.
27. Muredda M., Nunoya K., Burtch-Wright R.A., Kurz E.U., Cole S.P., Deeley R.G. Cloning and characterization of the murine and rat mrp1 promoter regions. Mol Pharmacol 2003, 64:1259-1269.
28. Tazzari P.L., Cappellini A., Ricci F., Evangelisti C., Papa V., Grafone T., et al. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007, 21:427-438.
29. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
30. Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003, 22:7512-7523.
31. Meurette O., Lefeuvre-Orfila L., Rebillard A., Lagadic-Gossmann D., Dimanche-Boitrel M.T. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations. Clin Cancer Res 2005, 11:3075-3083.
32. Godwin A.K., Meister A., O'Dwyer P.J., Huang C.S., Hamilton T.C., Anderson M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992, 89:3070-3074.
33. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat Rev Drug Discov 2009, 8:579-591.
34. Wang J., Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther 2008, 7:1875-1884.